Literature DB >> 15298608

Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis.

T Masaoka1, H K SuzukiKurabayashi, A G Kamiya, H Ishii.   

Abstract

BACKGROUND: After unsuccessful first-line treatment of Helicobacter pylori infection, the percentage of clarithromycin-resistant strains has been reported as between 30% and 70% in Japan and other countries. A high prevalence of clarithromycin-resistant strains is reported to be associated with eradication failure. AIM: We examined antibiotic susceptibility testing using a combination of dilution agar methods with PCR-restriction fragment length polymorphism (RFLP) analysis.
METHODS: We enrolled 41 patients in whom first-line treatment with LAC (lansoprazole, amoxycillin and clarithromycin) was unsuccessful. Endoscopic biopsied specimens were used to examine antibiotic susceptibility to clarithromycin by dilution agar methods. PCR-RFLP analysis was performed to determine the presence of point mutations, which are primarily responsible for resistance to clarithromycin.
RESULTS: Clarithromycin-resistance rate after failure of the LAC regimen was 73.2%. Drug susceptibilities of three strains obtained by PCR-RFLP analysis were different from those by dilution agar methods. One strain with MIC values to clarithromycin of 0.05 micro g/mL had a point mutation, A2144G. This strain was not eradicated by repeating LAC, but was eradicated by substituting metronidazole for clarithromycin.
CONCLUSIONS: Dilution agar methods should be combined with PCR-RFLP analysis before second-line eradication to increase the accuracy of clarithromycin-susceptibility testing and to improve eradication efficacy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15298608     DOI: 10.1111/j.1365-2036.2004.01994.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

1.  Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

Authors:  Yuqin Li; Xiayue Huang; Linhua Yao; Ruihua Shi; Guoxin Zhang
Journal:  Wien Klin Wochenschr       Date:  2010-07-16       Impact factor: 1.704

2.  Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Hitoshi Tsugawa; Hiroe Muraoka; Juntaro Matsuzaki; Kenro Hirata; Fumiaki Ikeda; Masahiko Takahashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-04-12       Impact factor: 5.191

3.  Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Kumiko Kurabayashi; Tatsuhiro Masaoka; Hiroe Muraoka; Mikiji Mori; Eisuke Iwasaki; Intetsu Kobayashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Ayako Umezawa; Hiroe Muraoka; Eisuke Iwasaki; Tatsuhiro Masaoka; Intetsu Kobayashi; Toshifumi Hibi
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

5.  Helicobacter pylori resistance to rifabutin in the last 7 years.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Juntaro Matsuzaki; Hiroe Muraoka; Hitoshi Tsugawa; Kenro Hirata; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

Review 6.  Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki
Journal:  Front Mol Biosci       Date:  2014-10-24

7.  Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Toshifumi Hibi
Journal:  J Clin Biochem Nutr       Date:  2009-02-28       Impact factor: 3.114

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.